Linked Life Data

21300665

Source:http://linkedlifedata.com/resource/pubmed/id/21300665

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21300665rdf:typepubmed:Citationlld:pubmed
pubmed-article:21300665lifeskim:mentionsumls-concept:C0390423lld:lifeskim
pubmed-article:21300665lifeskim:mentionsumls-concept:C1705845lld:lifeskim
pubmed-article:21300665lifeskim:mentionsumls-concept:C1801960lld:lifeskim
pubmed-article:21300665lifeskim:mentionsumls-concept:C0003009lld:lifeskim
pubmed-article:21300665lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:21300665lifeskim:mentionsumls-concept:C0001128lld:lifeskim
pubmed-article:21300665lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:21300665lifeskim:mentionsumls-concept:C1332036lld:lifeskim
pubmed-article:21300665lifeskim:mentionsumls-concept:C0205171lld:lifeskim
pubmed-article:21300665lifeskim:mentionsumls-concept:C1706204lld:lifeskim
pubmed-article:21300665lifeskim:mentionsumls-concept:C1555721lld:lifeskim
pubmed-article:21300665pubmed:issue3lld:pubmed
pubmed-article:21300665pubmed:dateCreated2011-2-17lld:pubmed
pubmed-article:21300665pubmed:abstractTextNovel AT(2)R ligands were designed by substituting individual ?-amino acid in the sequence of the native ligand angiotensin II (Ang II). Relative ATR selectivity and functional vascular assays (in vitro AT(2)R-mediated vasorelaxation and in vivo vasodepressor action) were determined. In competition binding experiments using either AT(1)R- or AT(2)R- transfected HEK-293 cells, only ?-Asp(1)-Ang II and Ang II fully displaced [(125)I]-Ang II from AT(1)R. In contrast, ?-substitutions at each position of Ang II exhibited AT(2)R affinity, with ?-Tyr(4)-Ang II and ?-Ile(5)-Ang II exhibiting ? 1000-fold AT(2)R selectivity. In mouse aortic rings, ?-Tyr(4)-Ang II and ?-Ile(5)-Ang II evoked vasorelaxation that was sensitive to blockade by the AT(2)R antagonist PD123319 and the nitric oxide synthase inhibitor L-NAME. When tested with a low level of AT(1)R blockade, ?-Ile(5)-Ang II (15 pmol/kg per minute IV for 4 hours) reduced blood pressure (BP) in conscious spontaneously hypertensive rats (?-Ile(5)-Ang II plus candesartan, -24 ± 4 mm Hg) to a greater extent than candesartan alone (-11 ± 3 mm Hg, n=7, P<0.05), an effect that was abolished by concomitant PD123319 infusion. However, in an identical experimental protocol, ?-Tyr(4)-Ang II had no influence on BP (n=10), and it was less stable than ?-Ile(5)-Ang II in plasma stability assays. Thus, this study demonstrated that a single ?-amino acid substitution resulted in a compound that demonstrated both in vitro vasorelaxation and in vivo depressor activity via AT(2)R. This approach to the design and synthesis of novel AT(2)R-selective peptidomimetics shows great potential to provide insight into AT(2)R function.lld:pubmed
pubmed-article:21300665pubmed:languageenglld:pubmed
pubmed-article:21300665pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21300665pubmed:citationSubsetIMlld:pubmed
pubmed-article:21300665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21300665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21300665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21300665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21300665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21300665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21300665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21300665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21300665pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21300665pubmed:statusMEDLINElld:pubmed
pubmed-article:21300665pubmed:monthMarlld:pubmed
pubmed-article:21300665pubmed:issn1524-4563lld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:ThomasWalter...lld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:PerlmutterPat...lld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:AguilarMarie-...lld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:UnabiaSharonSlld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:WiddopRobert...lld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:JonesEmma SESlld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:ClaytonDaniel...lld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:Del...lld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:HauslerNichol...lld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:KirschJulian...lld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:BosnyakSanjaSlld:pubmed
pubmed-article:21300665pubmed:authorpubmed-author:WelungodaIres...lld:pubmed
pubmed-article:21300665pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21300665pubmed:volume57lld:pubmed
pubmed-article:21300665pubmed:ownerNLMlld:pubmed
pubmed-article:21300665pubmed:authorsCompleteYlld:pubmed
pubmed-article:21300665pubmed:pagination570-6lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:meshHeadingpubmed-meshheading:21300665...lld:pubmed
pubmed-article:21300665pubmed:year2011lld:pubmed
pubmed-article:21300665pubmed:articleTitleA single beta-amino acid substitution to angiotensin II confers AT2 receptor selectivity and vascular function.lld:pubmed
pubmed-article:21300665pubmed:affiliationDepartment of Pharmacology, Monash University, Clayton, Victoria 3800, Australia.lld:pubmed
pubmed-article:21300665pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21300665pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed